Judith Cohn

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.

E. Israel, L. Dubé, J. Drazen, 1996, JAMA.

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.

J. Murray, S. Peters, R. Dworski, 1996, The Journal of allergy and clinical immunology.

Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.

J. Drazen, M. Kaliner, C. Lilly, 1994, The Journal of allergy and clinical immunology.

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.

W. Calhoun, G. Gleich, M. Minkwitz, 1998, American journal of respiratory and critical care medicine.